Q&A With Richard Lewis, MD, FAAN, of Cedars Sinai: Taking the Next Steps in CIDP Treatment

Video

As more is learned about the diagnosis and treatment of CIDP the medical community is also learning how best to work with patients with the condition.

As more is learned about the diagnosis and treatment of CIDP the medical community is also learning how best to work with patients with the condition.

There are mechanisms in place to monitor treatment success but Richard Lewis, MD, from Cedars Sinai said it is important to have people familiar with the condition to monitor patient health in order to assure them the best possible outcome. Lewis spoke during the American Academy of Neurology's annual meeting in Washington DC. 

Related Videos
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
John Kane, MD: Shifts in Antipsychotics for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.